Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 288

1.

Mutational profiles of persistent/recurrent laryngeal squamous cell carcinoma.

Smith JD, Birkeland AC, Rosko AJ, Hoesli RC, Foltin SK, Swiecicki P, Mierzwa M, Chinn SB, Shuman AG, Malloy KM, Casper KA, McLean SA, Wolf GT, Bradford CR, Prince ME, Brenner JC, Spector ME.

Head Neck. 2018 Dec 12. doi: 10.1002/hed.25444. [Epub ahead of print]

PMID:
30548484
2.

Histologic pattern of invasion and epithelial-mesenchymal phenotype predict prognosis in squamous carcinoma of the head and neck.

Wolf GT, Winter W, Bellile E, Nguyen A, Donnelly CR, McHugh JB, Thomas D, Amlani L, Rozek L, Lei YL; Head and Neck SPORE Program.

Oral Oncol. 2018 Dec;87:29-35. doi: 10.1016/j.oraloncology.2018.10.010. Epub 2018 Oct 22.

PMID:
30527240
3.

Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.

Mann JE, Smith JD, Birkeland AC, Bellile E, Swiecicki P, Mierzwa M, Chinn SB, Shuman AG, Malloy KM, Casper KA, McLean SA, Moyer JS, Wolf GT, Bradford CR, Prince ME, Carey TE, McHugh JB, Spector ME, Brenner JC.

Cancer Immunol Immunother. 2018 Oct 25. doi: 10.1007/s00262-018-2256-3. [Epub ahead of print]

PMID:
30361882
4.

Individualized survival prediction for patients with oropharyngeal cancer in the human papillomavirus era.

Beesley LJ, Hawkins PG, Amlani LM, Bellile EL, Casper KA, Chinn SB, Eisbruch A, Mierzwa ML, Spector ME, Wolf GT, Shuman AG, Taylor JMG.

Cancer. 2019 Jan 1;125(1):68-78. doi: 10.1002/cncr.31739. Epub 2018 Oct 6.

PMID:
30291798
5.

Expressed HNSCC variants by HPV-status in a well-characterized Michigan cohort.

Qin T, Zhang Y, Zarins KR, Jones TR, Virani S, Peterson LA, McHugh JB, Chepeha D, Wolf GT, Rozek LS, Sartor MA.

Sci Rep. 2018 Jul 30;8(1):11458. doi: 10.1038/s41598-018-29599-w.

6.

IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.

Wolf GT, Moyer JS, Kaplan MJ, Newman JG, Egan JE, Berinstein NL, Whiteside TL.

Onco Targets Ther. 2018 Jun 28;11:3731-3746. doi: 10.2147/OTT.S165411. eCollection 2018. Review.

7.

Redefining Perineural Invasion: Integration of Biology With Clinical Outcome.

Schmitd LB, Beesley LJ, Russo N, Bellile EL, Inglehart RC, Liu M, Romanowicz G, Wolf GT, Taylor JMG, D'Silva NJ.

Neoplasia. 2018 Jul;20(7):657-667. doi: 10.1016/j.neo.2018.04.005. Epub 2018 May 23.

8.

Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.

Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, Zhao X, Bellile E, Hu H, Chen H, Polverini PJ, Chen Q, Young S, Carey TE, Nör JE, Ferris RL, Wolf GT, Sun D, Lei YL.

Clin Cancer Res. 2018 Sep 1;24(17):4242-4255. doi: 10.1158/1078-0432.CCR-17-2807. Epub 2018 May 16.

PMID:
29769207
9.

Vitamin D intake and survival and recurrence in head and neck cancer patients.

Yokosawa EB, Arthur AE, Rentschler KM, Wolf GT, Rozek LS, Mondul AM.

Laryngoscope. 2018 Nov;128(11):E371-E376. doi: 10.1002/lary.27256. Epub 2018 May 14.

PMID:
29756240
10.

Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen.

Berinstein NL, McNamara M, Nguyen A, Egan J, Wolf GT.

Oncoimmunology. 2018 Feb 21;7(5):e1423173. doi: 10.1080/2162402X.2017.1423173. eCollection 2018.

11.

Retraction notice to: Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents.

Ali S, Varghese L, Pereira L, Tulunay-Ugur OE, Kucuk O, Carey TE, Wolf GT, Sarkar FH.

Cancer Lett. 2018 Jun 1;423:154. doi: 10.1016/j.canlet.2018.03.018.

12.

Higher carbohydrate intake is associated with increased risk of all-cause and disease-specific mortality in head and neck cancer patients: results from a prospective cohort study.

Arthur AE, Goss AM, Demark-Wahnefried W, Mondul AM, Fontaine KR, Chen YT, Carroll WR, Spencer SA, Rogers LQ, Rozek LS, Wolf GT, Gower BA; University of Michigan Head and Neck SPORE Program.

Int J Cancer. 2018 Sep 1;143(5):1105-1113. doi: 10.1002/ijc.31413. Epub 2018 Apr 17.

PMID:
29604042
13.

Reply to L. Licitra et al.

Forastiere AA, Fisher SG, Wolf GT.

J Clin Oncol. 2018 May 1;36(13):1377-1378. doi: 10.1200/JCO.2018.77.8316. Epub 2018 Mar 20. No abstract available.

PMID:
29558279
14.

Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

Tan YS, Sansanaphongpricha K, Prince MEP, Sun D, Wolf GT, Lei YL.

J Dent Res. 2018 Jun;97(6):627-634. doi: 10.1177/0022034518764416. Epub 2018 Mar 13.

PMID:
29533731
15.

Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma.

Hoesli R, Birkeland AC, Rosko AJ, Issa M, Chow KL, Michmerhuizen NL, Mann JE, Chinn SB, Shuman AG, Prince ME, Wolf GT, Bradford CR, McHugh JB, Brenner JC, Spector ME.

Oral Oncol. 2018 Feb;77:83-89. doi: 10.1016/j.oraloncology.2017.12.003. Epub 2017 Dec 23.

PMID:
29362129
16.

Head and neck paragangliomas: A two-decade institutional experience and algorithm for management.

Smith JD, Harvey RN, Darr OA, Prince ME, Bradford CR, Wolf GT, Else T, Basura GJ.

Laryngoscope Investig Otolaryngol. 2017 Nov 11;2(6):380-389. doi: 10.1002/lio2.122. eCollection 2017 Dec.

17.

Hypothyroidism and Wound Healing After Salvage Laryngectomy.

Rosko AJ, Birkeland AC, Bellile E, Kovatch KJ, Miller AL, Jaffe CC, Shuman AG, Chinn SB, Stucken CL, Malloy KM, Moyer JS, Casper KA, Prince MEP, Bradford CR, Wolf GT, Chepeha DB, Spector ME.

Ann Surg Oncol. 2018 May;25(5):1288-1295. doi: 10.1245/s10434-017-6278-4. Epub 2017 Dec 20.

PMID:
29264671
18.

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

Forastiere AA, Ismaila N, Wolf GT.

J Oncol Pract. 2018 Feb;14(2):123-128. doi: 10.1200/JOP.2017.027912. Epub 2017 Nov 27. No abstract available.

PMID:
29172913
19.

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Forastiere AA, Ismaila N, Lewin JS, Nathan CA, Adelstein DJ, Eisbruch A, Fass G, Fisher SG, Laurie SA, Le QT, O'Malley B, Mendenhall WM, Patel S, Pfister DG, Provenzano AF, Weber R, Weinstein GS, Wolf GT.

J Clin Oncol. 2018 Apr 10;36(11):1143-1169. doi: 10.1200/JCO.2017.75.7385. Epub 2017 Nov 27.

PMID:
29172863
20.

Individualized outcome prognostication for patients with laryngeal cancer.

Hoban CW, Beesley LJ, Bellile EL, Sun Y, Spector ME, Wolf GT, Taylor JMG, Shuman AG.

Cancer. 2018 Feb 15;124(4):706-716. doi: 10.1002/cncr.31087. Epub 2017 Nov 7.

PMID:
29112231
21.

Predictors of survival after total laryngectomy for recurrent/persistent laryngeal squamous cell carcinoma.

Birkeland AC, Beesley L, Bellile E, Rosko AJ, Hoesli R, Chinn SB, Shuman AG, Prince ME, Wolf GT, Bradford CR, Brenner JC, Spector ME.

Head Neck. 2017 Dec;39(12):2512-2518. doi: 10.1002/hed.24918. Epub 2017 Sep 30.

22.

Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma.

Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J 4th, Pai SI, Sidransky D, Westra WH, William WN Jr, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM; Head and Neck Cancer SPORE HIV supplement consortium.

Head Neck. 2017 Dec;39(12):2433-2443. doi: 10.1002/hed.24911. Epub 2017 Sep 25.

23.

HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers.

Koneva LA, Zhang Y, Virani S, Hall PB, McHugh JB, Chepeha DB, Wolf GT, Carey TE, Rozek LS, Sartor MA.

Mol Cancer Res. 2018 Jan;16(1):90-102. doi: 10.1158/1541-7786.MCR-17-0153. Epub 2017 Sep 19.

24.

Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond.

de Bree R, Wolf GT, de Keizer B, Nixon IJ, Hartl DM, Forastiere AA, Haigentz M Jr, Rinaldo A, Rodrigo JP, Saba NF, Suárez C, Vermorken JB, Ferlito A.

Head Neck. 2017 Nov;39(11):2329-2349. doi: 10.1002/hed.24883. Epub 2017 Aug 17. Review.

25.

Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck.

Manohar PM, Sapir E, Bellile E, Swiecicki PL, Pearson AT, Prince ME, Shuman AG, Bradford CR, Chepeha DB, Wolf GT, Eisbruch A, Worden FP, Spector ME.

Otolaryngol Head Neck Surg. 2017 Dec;157(6):995-997. doi: 10.1177/0194599817722948. Epub 2017 Aug 15.

PMID:
28809131
26.

Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx.

Gainor DL, Marchiano E, Bellile E, Spector ME, Taylor JMG, Wolf GT, Hogikyan ND, Prince ME, Bradford CR, Eisbruch A, Worden F, Shuman AG.

Otolaryngol Head Neck Surg. 2017 Oct;157(4):625-630. doi: 10.1177/0194599817711374. Epub 2017 Jun 13.

27.

Preoperative Tracheostomy Is Associated with Poor Disease-Free Survival in Recurrent Laryngeal Cancer.

Birkeland AC, Rosko AJ, Beesley L, Bellile E, Chinn SB, Shuman AG, Prince ME, Wolf GT, Bradford CR, Brenner JC, Spector ME.

Otolaryngol Head Neck Surg. 2017 Sep;157(3):432-438. doi: 10.1177/0194599817709236. Epub 2017 Jun 6.

28.

Family history of cancer and head and neck cancer survival.

Getz KR, Rozek LS, Peterson LA, Bellile EL, Taylor JMG, Wolf GT, Mondul AM.

Laryngoscope. 2017 Aug;127(8):1816-1820. doi: 10.1002/lary.26524. Epub 2017 Mar 7.

29.

Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer.

Wolf GT, Bellile E, Eisbruch A, Urba S, Bradford CR, Peterson L, Prince ME, Teknos TN, Chepeha DB, Hogikyan ND, McLean SA, Moyer J, Taylor JMG, Worden FP.

JAMA Otolaryngol Head Neck Surg. 2017 Apr 1;143(4):355-366. doi: 10.1001/jamaoto.2016.3669.

30.

Individualized risk prediction of outcomes for oral cavity cancer patients.

Prince V, Bellile EL, Sun Y, Wolf GT, Hoban CW, Shuman AG, Taylor JM.

Oral Oncol. 2016 Dec;63:66-73. doi: 10.1016/j.oraloncology.2016.11.005. Epub 2016 Nov 23.

31.

E6 and E7 Antibody Levels Are Potential Biomarkers of Recurrence in Patients with Advanced-Stage Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma.

Spector ME, Sacco AG, Bellile E, Taylor JMG, Jones T, Sun K, Brown WC, Birkeland AC, Bradford CR, Wolf GT, Prince ME, Moyer JS, Malloy K, Swiecicki P, Eisbruch A, McHugh JB, Chepeha DB, Rozek L, Worden FP.

Clin Cancer Res. 2017 Jun 1;23(11):2723-2729. doi: 10.1158/1078-0432.CCR-16-1617. Epub 2016 Nov 21.

32.

Does Quitting Smoking Make a Difference Among Newly Diagnosed Head and Neck Cancer Patients?

Choi SH, Terrell JE, Bradford CR, Ghanem T, Spector ME, Wolf GT, Lipkus IM, Duffy SA.

Nicotine Tob Res. 2016 Dec;18(12):2216-2224. Epub 2016 Aug 18.

33.

Cytokines in saliva increase in head and neck cancer patients after treatment.

Russo N, Bellile E, Murdoch-Kinch CA, Liu M, Eisbruch A, Wolf GT, D'Silva NJ.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Oct;122(4):483-490.e1. doi: 10.1016/j.oooo.2016.05.020. Epub 2016 Jun 9.

34.

Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer.

Lei Y, Xie Y, Tan YS, Prince ME, Moyer JS, Nör J, Wolf GT.

Oral Oncol. 2016 Oct;61:159-65. doi: 10.1016/j.oraloncology.2016.08.003. Epub 2016 Aug 21. Review.

35.

Multiple imputation of missing covariates for the Cox proportional hazards cure model.

Beesley LJ, Bartlett JW, Wolf GT, Taylor JM.

Stat Med. 2016 Nov 20;35(26):4701-4717. doi: 10.1002/sim.7048. Epub 2016 Jul 21.

36.

Cigarette use, comorbidities, and prognosis in a prospective head and neck squamous cell carcinoma population.

Peterson LA, Bellile EL, Wolf GT, Virani S, Shuman AG, Taylor JM, Rozek LS; University of Michigan Head and Neck Specialized Program of Research Excellence Program.

Head Neck. 2016 Dec;38(12):1810-1820. doi: 10.1002/hed.24515. Epub 2016 Jul 19.

37.

Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma.

Walline HM, Komarck CM, McHugh JB, Bellile EL, Brenner JC, Prince ME, McKean EL, Chepeha DB, Wolf GT, Worden FP, Bradford CR, Carey TE.

Mol Cancer Res. 2016 Oct;14(10):941-952. Epub 2016 Jul 15.

38.

Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials.

Sanabria A, Chaves ALF, Kowalski LP, Wolf GT, Saba NF, Forastiere AA, Beitler JJ, Nibu KI, Bradford CR, Suárez C, Rodrigo JP, Strojan P, Rinaldo A, de Bree R, Haigentz M Jr, Takes RP, Ferlito A.

Auris Nasus Larynx. 2017 Feb;44(1):18-25. doi: 10.1016/j.anl.2016.06.005. Epub 2016 Jul 5. Review.

PMID:
27397024
39.

Classification of TP53 mutations and HPV predict survival in advanced larynx cancer.

Scheel A, Bellile E, McHugh JB, Walline HM, Prince ME, Urba S, Wolf GT, Eisbruch A, Worden F, Carey TE, Bradford C.

Laryngoscope. 2016 Sep;126(9):E292-9. doi: 10.1002/lary.25915. Epub 2016 Jun 27.

40.

A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.

Swiecicki PL, Bellile E, Sacco AG, Pearson AT, Taylor JM, Jackson TL, Chepeha DB, Spector ME, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Sukari A, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey TE, Wang S, Nör JE, Worden FP.

Invest New Drugs. 2016 Aug;34(4):481-9. doi: 10.1007/s10637-016-0364-5. Epub 2016 May 26.

41.

Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures.

Zhang Y, Koneva LA, Virani S, Arthur AE, Virani A, Hall PB, Warden CD, Carey TE, Chepeha DB, Prince ME, McHugh JB, Wolf GT, Rozek LS, Sartor MA.

Clin Cancer Res. 2016 Sep 15;22(18):4735-45. doi: 10.1158/1078-0432.CCR-16-0323. Epub 2016 Apr 18.

42.

Socioeconomic and Other Demographic Disparities Predicting Survival among Head and Neck Cancer Patients.

Choi SH, Terrell JE, Fowler KE, McLean SA, Ghanem T, Wolf GT, Bradford CR, Taylor J, Duffy SA.

PLoS One. 2016 Mar 1;11(3):e0149886. doi: 10.1371/journal.pone.0149886. eCollection 2016.

43.

Exploration for an Algorithm for Deintensification to Exclude the Retropharyngeal Site From Advanced Oropharyngeal Squamous Cell Carcinoma Treatment.

Spector ME, Chinn SB, Bellile E, Gallagher KK, Kang SY, Moyer JS, Prince ME, Wolf GT, Bradford CR, McHugh JB, Carey TE, Worden FP, Eisbruch A, Ibrahim M, Chepeha DB.

JAMA Otolaryngol Head Neck Surg. 2016 Apr;142(4):313-8. doi: 10.1001/jamaoto.2015.3602.

44.

Occult Nodal Disease Prevalence and Distribution in Recurrent Laryngeal Cancer Requiring Salvage Laryngectomy.

Birkeland AC, Rosko AJ, Issa MR, Shuman AG, Prince ME, Wolf GT, Bradford CR, McHugh JB, Brenner JC, Spector ME.

Otolaryngol Head Neck Surg. 2016 Mar;154(3):473-9. doi: 10.1177/0194599815627811. Epub 2016 Feb 16.

45.

Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.

Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, Peterson L, Carey TE, Walline H, Moyer J, Spector M, Perim D, Prince M, McLean S, Bradford CR, Taylor JM, Wolf GT; Head and Neck SPORE Program Investigators.

Head Neck. 2016 Jul;38(7):1074-84. doi: 10.1002/hed.24406. Epub 2016 Feb 16.

46.

Pretreatment serum xanthophyll concentrations as predictors of head and neck cancer recurrence and survival.

Arthur AE, Bellile EL, Rozek LS, Peterson KE, Ren J, Harris E, Mueller C, Jolly S, Peterson LA, Wolf GT, Djuric Z.

Head Neck. 2016 Apr;38 Suppl 1:E1591-7. doi: 10.1002/hed.24283. Epub 2015 Nov 28.

47.

Stability of methylation markers in head and neck squamous cell carcinoma.

Virani S, Light E, Peterson LA, Sartor MA, Taylor JM, McHugh JB, Wolf GT, Rozek LS; Investigators of the University of Michigan Head and Neck Specialized Programs of Research Excellence (SPORE) Program.

Head Neck. 2016 Apr;38 Suppl 1:E1325-31. doi: 10.1002/hed.24223. Epub 2015 Nov 13.

48.

NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.

Virani S, Bellile E, Bradford CR, Carey TE, Chepeha DB, Colacino JA, Helman JI, McHugh JB, Peterson LA, Sartor MA, Taylor JM, Walline HM, Wolf GT, Rozek LS.

BMC Cancer. 2015 Oct 30;15:825. doi: 10.1186/s12885-015-1806-8.

49.

A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.

Swiecicki PL, Zhao L, Belile E, Sacco AG, Chepeha DB, Dobrosotskaya I, Spector M, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey T, Worden FP.

Invest New Drugs. 2015 Dec;33(6):1248-56. doi: 10.1007/s10637-015-0293-8. Epub 2015 Oct 10.

PMID:
26453566
50.

Association Between Multimodality Neck Treatment and Work and Leisure Impairment: A Disease-Specific Measure to Assess Both Impairment and Rehabilitation After Neck Dissection.

Gallagher KK, Sacco AG, Lee JS, Taylor R, Chanowski EJ, Bradford CR, Prince ME, Moyer JS, Wolf GT, Worden FP, Eisbruch A, Chepeha DB.

JAMA Otolaryngol Head Neck Surg. 2015 Oct;141(10):888-93.

PMID:
26426565

Supplemental Content

Support Center